A post-incorporation study on the use of palivizumab in the Brazilian public health system.
暂无分享,去创建一个
C. Polanczyk | L. Cruz | M. A. Ferreira | J. Batista | Cilene da Silva Xavier | Ires Tarsila Alves de Souza
[1] G. La Rosa,et al. Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies , 2020, PloS one.
[2] E. Simões,et al. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six‐Year Follow‐up Study , 2017, American journal of respiratory and critical care medicine.
[3] R. Mattiello,et al. Lack of association between viral load and severity of acute bronchiolitis in infants , 2016, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[4] E. França,et al. Monitoramento de vírus respiratórios na região metropolitana de Belo Horizonte, 2011 a 2013 , 2016 .
[5] M. A. P. Safádi. Imunoprofilaxia do vírus sincicial respiratório com palivizumabe: o que há de novo? , 2014 .
[6] A. D. Santos,et al. Infecções respiratórias em crianças menores de dois anos de idade submetidas a profilaxia com palivizumabe , 2014 .
[7] E. Simões,et al. Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants , 2013, Pediatrics.
[8] M. Rojas-Reyes,et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. , 2013, The Cochrane database of systematic reviews.
[9] K. Fahrbach,et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[10] G. Boivin,et al. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab , 2008, Journal of Clinical Virology.
[11] K.,et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. , 2003, The Journal of pediatrics.
[12] D. Saúde,et al. GABINETE DO MINISTRO , 2004 .
[13] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.
[14] Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.